Device Implantable Cardioverter Defibrillators (Icds)

Visa Af Mri Vr Surescan

Payments companies reported to CMS as associated with Visa Af Mri Vr Surescan. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$6,025associated payments (2023-2025)
82clinicians with associated payments
1company reporting

By year

2023 $1,911
2024 $4,094
2025 $20.48

Payments reported as associated with Visa Af Mri Vr Surescan, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Clinical Cardiac Electrophysiology $2,675
Cardiovascular Disease $1,529
Nurse Practitioner $369
Family $341
Advanced Heart Failure and Transplant Cardiology $341
Interventional Cardiology $287

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Visa Af Mri Vr Surescan

These are the largest totals companies reported as associated with Visa Af Mri Vr Surescan. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Hector Banchs Carolina, PR Clinical Cardiac Electrophysiology $629.03
Yolanda Figueroa Humacao, PR Advanced Heart Failure and Transplant Cardiology $341.01
Amanda Edgar Hattiesburg, MS Family $339.30
Jose Marcial Suarez Cayey, PR Clinical Cardiac Electrophysiology $234.58
Giannina Coppola-Fasick Carolina, PR Allergy & Immunology (Internal Medicine) $224.28
Ariel Gonzalez Cordero Carolina, PR Cardiovascular Disease $224.27
Luis Molinary Fernandez Bayamon, PR Cardiovascular Disease $224.27
Hilton Franqui-Rivera Toa Alta, PR Clinical Cardiac Electrophysiology $224.27
Rigoberto Ramos Gonzalez Adjuntas, PR Cardiovascular Disease $224.27
Suleyka Olivero-Rivera Bayamon, PR Clinical Cardiac Electrophysiology $221.58

Prescribed Visa Af Mri Vr Surescan?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.